Congestive Heart Failure (Heart Failure) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) – Pipeline Review, H1 2017’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)

The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects

The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allosteros Therapeutics Inc

Amgen Inc

Anexon Inc

AnGes MG Inc

Araim Pharmaceuticals Inc

Arbor Pharmaceuticals LLC

Ascelegen Therapeutics Inc

AstraZeneca Plc

Athersys Inc

Bayer AG

BEAT BioTherapeutics Corp

BioCardia Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Capricor Therapeutics Inc

Celixir Ltd

Celyad SA

Daiichi Sankyo Company Ltd

F. Hoffmann-La Roche Ltd

FibroGen Inc

GlaxoSmithKline Plc

Heart Metabolics Ltd

Hemostemix Ltd

Innopharmax Inc

Intrexon Corp

Jiangsu Hengrui Medicine Co Ltd

Juventas Therapeutics Inc

La Jolla Pharmaceutical Company

Lead Discovery Center GmbH

Lee's Pharmaceutical Holdings Ltd

Les Laboratoires Servier SAS

Lonestar Heart Inc

Madeleine Pharmaceuticals Inc

Mast Therapeutics Inc

Merck & Co Inc

Mesoblast Ltd

MorphoSys AG

NanoCor Therapeutics Inc

Neurocrine Biosciences Inc

Novartis AG

Nuo Therapeutics Inc

Nyken BV

Orion Oyj

Palatin Technologies Inc

PharmaIN Corp

PhaseBio Pharmaceuticals Inc

Quantum Genomics SA

Recardio GmbH

RedHill Biopharma Ltd

Renova Therapeutics Inc

scPharmaceuticals Inc

Stealth BioTherapeutics Inc

Stemedica Cell Technologies Inc

Target Heart Biotec Srl

Theravance Biopharma Inc

TiGenix NV

Torrent Pharmaceuticals Ltd

Trevena Inc

U.S. Stem Cell Inc

Vicore Pharma AB

Zensun (Shanghai) Sci & Tech Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Congestive Heart Failure (Heart Failure) - Overview 11

Congestive Heart Failure (Heart Failure) - Therapeutics Development 12

Pipeline Overview 12

Pipeline by Companies 13

Pipeline by Universities/Institutes 19

Products under Development by Companies 22

Products under Development by Universities/Institutes 29

Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 32

Assessment by Target 32

Assessment by Mechanism of Action 37

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 46

Allosteros Therapeutics Inc 46

Amgen Inc 46

Anexon Inc 47

AnGes MG Inc 47

Araim Pharmaceuticals Inc 48

Arbor Pharmaceuticals LLC 48

Ascelegen Therapeutics Inc 49

AstraZeneca Plc 49

Athersys Inc 50

Bayer AG 50

BEAT BioTherapeutics Corp 51

BioCardia Inc 51

Boehringer Ingelheim GmbH 52

Bristol-Myers Squibb Company 52

Capricor Therapeutics Inc 53

Celixir Ltd 53

Celyad SA 54

Daiichi Sankyo Company Ltd 54

F. Hoffmann-La Roche Ltd 55

FibroGen Inc 55

GlaxoSmithKline Plc 56

Heart Metabolics Ltd 56

Hemostemix Ltd 57

Innopharmax Inc 57

Intrexon Corp 58

Jiangsu Hengrui Medicine Co Ltd 58

Juventas Therapeutics Inc 59

La Jolla Pharmaceutical Company 59

Lead Discovery Center GmbH 60

Lee's Pharmaceutical Holdings Ltd 60

Les Laboratoires Servier SAS 61

Lonestar Heart Inc 61

Madeleine Pharmaceuticals Inc 62

Mast Therapeutics Inc 62

Merck & Co Inc 63

Mesoblast Ltd 63

MorphoSys AG 64

NanoCor Therapeutics Inc 64

Neurocrine Biosciences Inc 65

Novartis AG 65

Nuo Therapeutics Inc 66

Nyken BV 66

Orion Oyj 67

Palatin Technologies Inc 67

PharmaIN Corp 68

PhaseBio Pharmaceuticals Inc 68

Quantum Genomics SA 69

Recardio GmbH 69

RedHill Biopharma Ltd 70

Renova Therapeutics Inc 70

scPharmaceuticals Inc 71

Stealth BioTherapeutics Inc 71

Stemedica Cell Technologies Inc 72

Target Heart Biotec Srl 72

Theravance Biopharma Inc 73

TiGenix NV 73

Torrent Pharmaceuticals Ltd 74

Trevena Inc 74

U.S. Stem Cell Inc 75

Vicore Pharma AB 75

Zensun (Shanghai) Sci & Tech Co Ltd 76

Congestive Heart Failure (Heart Failure) - Drug Profiles 77

(hydralazine + isosorbide dinitrate) XR - Drug Profile 77

(sacubitril + valsartan) - Drug Profile 78

AAVS-100A1 - Drug Profile 85

ACP-01 - Drug Profile 87

AdipoCell - Drug Profile 90

AE-07 - Drug Profile 93

AK-10 - Drug Profile 94

aladorian sodium - Drug Profile 95

ALD-201 - Drug Profile 97

AMG-986 - Drug Profile 99

AntimiR-199a - Drug Profile 100

Antisense RNAi Gene Therapy to Inhibit ANGPTL2 for Heart Failure - Drug Profile 101

ANX-042 - Drug Profile 102

ARX-720 - Drug Profile 103

AZD-4831 - Drug Profile 104

BAY-1753011 - Drug Profile 105

BAY-868050 - Drug Profile 106

BBR-12 - Drug Profile 107

beperminogene perplasmid - Drug Profile 108

BMS-986231 - Drug Profile 114

C-21 - Drug Profile 116

C-Cure - Drug Profile 119

CAP-1002 - Drug Profile 125

Carfostin - Drug Profile 131

carvedilol CR - Drug Profile 132

carvedilol phosphate CR - Drug Profile 134

Cell Therapy for Heart failure - Drug Profile 135

cenderitide - Drug Profile 136

cibinetide - Drug Profile 140

CLR-325 - Drug Profile 143

CTX-101 - Drug Profile 144

dapagliflozin propanediol - Drug Profile 146

Drug to Inhibit Calpain for Right Heart Failure - Drug Profile 153

Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 154

ECRA-1 - Drug Profile 155

elamipretide - Drug Profile 156

empagliflozin - Drug Profile 164

enalapril maleate - Drug Profile 173

FG-6874 - Drug Profile 174

furosemide - Drug Profile 175

GDF-11 - Drug Profile 177

Gene Therapy for Heart Failure - Drug Profile 178

Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile 179

Gene Therapy to Activate GLP-1 for Congestive Heart Failure - Drug Profile 180

Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile 181

Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 182

Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 183

Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile 184

GSK-2798745 - Drug Profile 185

istaroxime - Drug Profile 186

ITD-1 - Drug Profile 188

ivabradine hydrochloride - Drug Profile 189

ivabradine hydrochloride SR - Drug Profile 192

JVS-100 - Drug Profile 193

K-1062 - Drug Profile 198

KBP-5074 - Drug Profile 199

L-2286 - Drug Profile 201

levosimendan - Drug Profile 202

milrinone ER - Drug Profile 207

Monoclonal Antibody to Activate Sodium Potassium ATPase for Congestive Heart Failure and Status Epilepticus - Drug Profile 208

Monoclonal Antibody to Inhibit Periostin1 for Congestive Heart Failure - Drug Profile 209

MP-3167 - Drug Profile 210

MPC-150IM - Drug Profile 211

MRS-2339 - Drug Profile 216

MyoCell - Drug Profile 217

MyoCell SDF-1 - Drug Profile 219

NBI-69734 - Drug Profile 220

neladenoson bialanate - Drug Profile 221

Neucardin - Drug Profile 222

NM-922 - Drug Profile 225

NP-202 - Drug Profile 226

NPA-7 - Drug Profile 228

NYK-1112 - Drug Profile 229

Oligonucleotides to Antagonise Beta 1 Adrenergic Receptor for Pediatric Heart Failure - Drug Profile 230

omecamtiv mecarbil MR - Drug Profile 231

PB-1046 - Drug Profile 239

Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 241

Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile 242

perhexiline maleate - Drug Profile 243

PF-05285401 - Drug Profile 245

PHIN-1138 - Drug Profile 257

pirfenidone - Drug Profile 258

PL-3994 - Drug Profile 265

PL-5028 - Drug Profile 267

poloxamer - Drug Profile 268

pyroglutaminated serpinin - Drug Profile 270

QGC-101 - Drug Profile 271

REC-02 - Drug Profile 272

Recombinant Protein for Congestive Heart Failure - Drug Profile 273

ROMKi-B - Drug Profile 274

RT-100 - Drug Profile 275

RT-110 - Drug Profile 277

RT-300 - Drug Profile 278

RT-400 - Drug Profile 279

S-38844 - Drug Profile 280

serelaxin - Drug Profile 281

serpinin - Drug Profile 286

SG-1002 - Drug Profile 287

Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 288

Small Molecule to Inhibit CYP11B2 for Heart Failure - Drug Profile 289

Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 290

Small Molecules for Diastolic Heart Failure - Drug Profile 291

Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 292

Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 293

Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 294

Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 295

Small Molecules to Inhibit GRK2 for Heart Failure - Drug Profile 296

Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 297

Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 298

Small molecules to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure, Breast Cancer and Chronic Obstructive Pulmonary Disease - Drug Profile 299

Small Molecules to Inhibit Porcupine for Oncology, Degenerative Disorders And Congestive Heart Failure - Drug Profile 300

Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 301

Small Molecules to Target Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 302

sodium nitrite - Drug Profile 303

SP-20202 - Drug Profile 307

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 308

Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 314

Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile 315

Stem Cell Therapy for Heart Failure - Drug Profile 316

Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 317

Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 318

Synthetic Peptide to Agonize Beta 2 Adrenergic Receptor for Congestive Heart Failure - Drug Profile 319

Synthetic Peptide to Agonize Guanylate Cyclase A for Cardiovascular Disorders - Drug Profile 320

TD-0714 - Drug Profile 321

TD-1439 - Drug Profile 323

TR-4 - Drug Profile 324

TRC-4186 - Drug Profile 325

TRV-120023 - Drug Profile 327

ularitide - Drug Profile 328

valsartan CR - Drug Profile 330

VCP-746 - Drug Profile 331

vericiguat - Drug Profile 332

Xcel-hCardP - Drug Profile 334

Congestive Heart Failure (Heart Failure) - Dormant Projects 335

Congestive Heart Failure (Heart Failure) - Discontinued Products 341

Congestive Heart Failure (Heart Failure) - Product Development Milestones 343

Featured News & Press Releases 343

Appendix 354

Methodology 354

Coverage 354

Secondary Research 354

Primary Research 354

Expert Panel Validation 354

Contact Us 354

Disclaimer 355

List of Tables

List of Tables

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Allosteros Therapeutics Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Amgen Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Anexon Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by AnGes MG Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Araim Pharmaceuticals Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Arbor Pharmaceuticals LLC, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Ascelegen Therapeutics Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by AstraZeneca Plc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Athersys Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Bayer AG, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by BEAT BioTherapeutics Corp, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by BioCardia Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Bristol-Myers Squibb Company, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Capricor Therapeutics Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Celixir Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Celyad SA, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by FibroGen Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by GlaxoSmithKline Plc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Heart Metabolics Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Hemostemix Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Innopharmax Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Intrexon Corp, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Juventas Therapeutics Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by La Jolla Pharmaceutical Company, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Lead Discovery Center GmbH, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Les Laboratoires Servier SAS, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Lonestar Heart Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Madeleine Pharmaceuticals Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Mast Therapeutics Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Merck & Co Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Mesoblast Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by MorphoSys AG, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by NanoCor Therapeutics Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Neurocrine Biosciences Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Novartis AG, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Nuo Therapeutics Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Nyken BV, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Orion Oyj, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Palatin Technologies Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by PharmaIN Corp, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Quantum Genomics SA, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Recardio GmbH, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by RedHill Biopharma Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Renova Therapeutics Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by scPharmaceuticals Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Stealth BioTherapeutics Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Stemedica Cell Technologies Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Target Heart Biotec Srl, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Theravance Biopharma Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by TiGenix NV, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Torrent Pharmaceuticals Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Trevena Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by U.S. Stem Cell Inc, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Vicore Pharma AB, H1 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H1 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H1 2017 (Contd..3), H1 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H1 2017 (Contd..4), H1 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H1 2017 (Contd..5), H1 2017

Congestive Heart Failure (Heart Failure) – Discontinued Products, H1 2017

Congestive Heart Failure (Heart Failure) – Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports